Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels – an association with mammographic density

REFERENCES

• Writing Group for the Women's Health Initiative Investiga-tors. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–333.
   Google Scholar
• Grimes DA, Lobo RA. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet. Gynecol 2002;100:1344–1353.
   PubMed Web of Science ®Google Scholar
• Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol 1999;106:1–21.
   PubMedGoogle Scholar
• de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interac-tions of tibolone. Steroids 2003;68:21–30.
   Google Scholar
• Lundström E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717–722.
   Google Scholar
• Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symp-toms. Br J Obstet Gynaecol 1998;105:904–911.
   Google Scholar
• Dören M, Rubig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554–559.
   Google Scholar
• von Schoultz B. Potency of different estrogen preparations. In: Studd JWW, Whitehead MI, editors. The menopause. Oxford: Blackwell Science; 1998. pp 130–137.
   Google Scholar
• Tchernof A, Depres J-P. Sex steroid hormones, sex hormone-binding globulin and the obesity in men and women. Horm Metab Res 2000;32:526–536.
   Google Scholar
• Rosner W. Plasma steroid-binding proteins. Endocrinol Metab Chin North Am 1991;20:697–720.
   PubMed Web of Science ®Google Scholar
• Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous throm-boembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482–490.
   PubMed Web of Science ®Google Scholar
• Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997;8:922–928.
   Google Scholar
• Pollak M. IGF-I physiology and breast cancer. Recent Results Cancer Res 1998;152:63–70.
   PubMedGoogle Scholar
• Hankinson SE, Willett WC, Manson JE, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393–1396.
   PubMed Web of Science ®Google Scholar
• Conner P, Christow AG, Skoog L, et al. Breast cell proliferation in postmenopausal women during HRT evalu-ated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78:159–165.
   PubMed Web of Science ®Google Scholar
• Zumoff B. Hormonal profiles in women with breast cancer. Obstet Gynecol Chin North Am 1994;21:751–772.
   PubMedGoogle Scholar
• Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroe-piandrosterone. Endocr Rev 2003;24:152–182.
   PubMed Web of Science ®Google Scholar
• Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995;52:459–467.
   PubMed Web of Science ®Google Scholar
• Jayo MJ, Register TC, Hughes CL, et al. Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. J Soc Gynecol Invest 2000;7:257–265.
   PubMedGoogle Scholar
• Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. Br J Cancer 2002; 87:876–882.
   PubMed Web of Science ®Google Scholar
• Carlström K, Sköldefors H. Determination of total estrone in peripheral serum from non-pregnant humans. J Steriod Biochem 1997;8:1127–1128.
   Google Scholar
• Södergdrd R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradio1-17 beta to human plasma proteins at body tempera-ture. J Steroid Biochem 1982;16:801–810.
   Google Scholar
• Stomati M, Hartmann B, Spinetti A, et al. Effects of hormonal replacement therapy on plasma sex hormone-binding globu-lin, androgen and insulin-like growth factor-1 levels in postmenopausal women. J Endocrinol Invest 1996; 19:535–541.
   PubMed Web of Science ®Google Scholar
• Bernardi F, Pieri M, Stomati M, et al. Effect of different hormonal replacement therapies on circulating allopregnano-lone and dehydroepiandrosterone levels in postmenopausal women. Gynecol Endocrinol 2003;17:65–77.
   PubMed Web of Science ®Google Scholar
• Lobo RA. Estrogen and the risk of coagulopathy. Am J Med 1992;92:283–285.
   PubMed Web of Science ®Google Scholar
• Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997;78:315–326.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996;24:1–19.
   PubMed Web of Science ®Google Scholar
• Carlström K, Karlsson R, von Schoultz B. Diurnal rhythm and effects of oral contraceptives on serum dehydroepian-drosterone sulfate (DHEAS) are related to alterations in serum albumin rather than changes in adrenocortical steroid secretion. Scand J Chin Lab Invest 2002;62:361–368.
   Google Scholar
• Dimitrakakis C, Zhou J, Wang J, et al. A physiological role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2002;10:292–298.
   Google Scholar
• Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991;134:818–824.
   PubMed Web of Science ®Google Scholar
• Lobaccaro JM, Lumbroso S, Belon C, et al. Male breast cancer and the androgen receptor gene. Nat Genet 1993;5: 109–110.
   PubMed Web of Science ®Google Scholar
• Haiman CA, Brown M, Hankinson SE, et al. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res 2002;62:1045–1049.
   PubMed Web of Science ®Google Scholar
• Isaksson E, von Schoultz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001;65:163–169.
   PubMed Web of Science ®Google Scholar
• Rannevik G, Carlström K, Doeberl A, Laurell CB. Plasma protein changes induced by two orally administered andro-gen derivatives. Scand J Chin Lab Invest 1996;56: 161–166.
   PubMed Web of Science ®Google Scholar
• Chetrite GS, Kloosterboer HJ, Philippe JC, Pasqualini JR. Effects of Org OD14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. Anticancer Res 1999;19:261–217.
   PubMed Web of Science ®Google Scholar
• Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283: 485–491.
   PubMed Web of Science ®Google Scholar